C35 expression in FFPE breast tissue sections was determined by immunohistochemistry
n | HER-2/neu+ (%) | C35+ (%) | Mean C35 reactivity | P (one-sample paired t) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Intraductal carcinoma | ||||||||||
Qualtek study | 57 | 21 | 53 | |||||||
AccuMax Array | 30 | 20 | 40 | |||||||
Asterand Array | 71 | 20 | 38 | |||||||
Total IDC | 158 | 20* | 44 | 1.46† | <0.0001 | |||||
Low grade (1) | 22 | 0 | 32 | 0.73 | ||||||
High grade (2 and 3) | 35 | 34 | 66 | 2.03† | <0.0001 | |||||
Stage I | 28 | 11 | 18 | 0.93 | ||||||
Stage II | 38 | 24 | 47 | 1.63† | <0.0001 | |||||
Stage III | 26 | 19 | 38 | 1.46† | 0.0035 | |||||
Stage IV | 4 | 25 | 50 | 1.75 | ||||||
Lobular carcinoma | ||||||||||
Qualtek Study | 14 | 0 | 50 | |||||||
AccuMax Array | 4 | 0 | 25 | |||||||
Asterand Array | 22 | 5 | 32 | |||||||
Total ILC | 40 | 5‡ | 38 | 1.16† | 0.0083 | |||||
Papillary carcinoma: AccuMax | 8 | 13* | 50 | 1.13 | ||||||
Medullary carcinoma: Asterand | 6 | 0 | 0 | |||||||
Mucinous carcinoma: Asterand | 2 | 0 | 50 | |||||||
Normal breast tissue | ||||||||||
Adjacent normal | 40 | 13 | ||||||||
Normal breast | 17 | 35 | ||||||||
Total normal breast | 57 | 19 | 0.61 |